Nanomedicine: Current Regulatory Scenario and Prophylactic Regulatory Strategies

Posted 31 January 2012 By Aastha Kohli and Shrenik Desai

In simple terms, nanomedicine (NM) is nanotechnology-enabled medicine. It is the science and technology of diagnosing, curing and preventing a disease, repairing damaged tissues and preserving human health using molecular tools and molecular knowledge of the human body. Our bodies are made of nanostructures like DNA (~10 nm) and red blood cells (~10,000 nm). Compared to the conventional therapies and diagnostic practices, NM offers an opportunity to operate on the same scale as these body nanostructures. Thus, NM enables targeted drug delivery, improved solubility, increased dissolution rate, improved bioavailability and more rapid onset of action. NM is a promising avenue for life-threatening disorders like cancer. Moreover, with major patents soon to expire, the healthcare industry needs innovative products and has enough reasons to invest in NM.

Share this article:

Categories: Technology, Features

Tags: Prophylactic, Molecular, Nanostructures, Nanoparticles, Nanomedicine, nanotechnology, medicine, disease, regulatory

Regulatory Exchange: Latest Updates From the Community